开窗/分支支架治疗EVAR后Ia型内漏的前瞻性多中心队列研究
该前瞻性多中心研究纳入85例因EVAR后迟发Ia型内漏接受F/BEVAR的患者,技术成功率94%,院内死亡率5%,3年生存率64%,免于再干预或动脉瘤相关死亡40%。F/BEVAR有效但再干预需求较高。
要点
- F/BEVAR治疗EVAR后Ia型内漏技术成功率94%,院内死亡率5%。
- 3年免于再干预或动脉瘤相关死亡仅40%,33%患者需再次手术。
- 靶内脏动脉3年二期通畅率96%,脊髓缺血发生率4.7%。
核心结论
- 定制F/BEVAR可有效治疗EVAR后Ia型内漏,但伴随较多二次腔内和开放手术干预。
主要发现
- 技术成功率为94%,失败3例包括1例持续Ia型内漏和2例支架植入失败。
- 院内死亡率为5%,心脏、肾脏和肺部并发症发生率分别为6%、14%和7%。
- 术后脊髓缺血发生4例(4.7%)。
- 3年生存率64%,总体免于再干预或动脉瘤相关死亡40%,免于特定F/BEVAR再干预73%。
- 随访期间27例(33%)需翻修手术,包括11例开窗支架和16例原EVAR支架,其中6例开放转归。
关键数值与推荐
- Ia型内漏在EVAR后59±25个月出现。
- 实施82例FEVAR(96%)和3例BEVAR(4%),共重建305条靶动脉,术中303条成功。
- 靶内脏动脉3年二期通畅率96%。
临床怎么用
- 对于EVAR后迟发Ia型内漏患者,F/BEVAR是一种可行治疗选择,但需告知再干预风险较高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Failed endovascular infrarenal aortic aneurysm repair (EVAR) due to development of late type Ia endoleak exposes patients to the risk of rupture and should be treated. The purpose of this study was to evaluate the results of fenestrated/branched EVAR (F/BEVAR) for treatment of failed EVAR with type Ia endoleak. METHODS: From January 2010 to December 2019, a prospective multicentre study was conducted (ClinicalTrials.gov identifier: NCT04532450) that included 85 consecutive patients who had undergone F/BEVAR to treat a type Ia endoleak following EVAR. The primary outcome was overall freedom from any re-intervention or death related to the F/BEVAR procedure. RESULTS: In 30 cases (35%) EVAR was associated with a short < 10 mm or angulated (> 60°) infrarenal aortic neck, poor placement of the initial stent graft (n = 3, 4%), sizing error (n = 2, 2%), and/or stent graft migration (n = 7, 8%). Type Ia endoleak was observed after a period of 59 ± 25 months following EVAR. The authors performed 82 FEVAR (96%) and three BEVAR (4%) procedures with revascularisation of 305 target arteries. Overall technical success was 94%, with three failures including one persistent Type Ia endoleak and two unsuccessful stent graft implantations. Intra-operative target artery revascularisation was successful in 303 of 305 attempts. The in hospital mortality rate was 5%. Cardiac, renal and pulmonary complications occurred in 6%, 14%, and 7% of patients, respectively. Post-operative spinal cord ischaemia occurred in four patients (4.7%). At three years, the survival rate was 64% with overall freedom from any re-intervention or aneurysm related death of 40%, and freedom from specific F/BEVAR re-intervention of 73%. At three years, the secondary patency rate of the target visceral arteries was 96%. During follow up, 27 patients (33%) required a revision procedure of the fenestrated (n = 11) or index EVAR stent graft (n = 16), including six open conversions. CONCLUSION: While manufactured F/BEVAR was effective in treating type Ia endoleak in patients with failed EVAR, it was at the cost of a number of secondary endovascular and open surgical procedures.
引用
- Hostalrich A, Mesnard T, Soler R, et al. Prospective Multicentre Cohort Study of Fenestrated and Branched Endografts After Failed Endovascular Infrarenal Aortic Aneurysm Repair with Type Ia Endoleak. Eur J Vasc Endovasc Surg. 2021. PMID: 34364770. doi:10.1016/j.ejvs.2021.06.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。